TISIDB

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Note=Localizes to lipid rafts (PubMed:12517957, PubMed:9168119). Removed from plasma membrane by HIV-1 Nef protein that increases clathrin-dependent endocytosis of this antigen to target it to lysosomal degradation. Cell surface expression is also down-modulated by HIV-1 Envelope polyprotein gp160 that interacts with, and sequesters CD4 in the endoplasmic reticulum.
Domain	PF05790 Immunoglobulin C2-set domain PF09191 CD4 PF00047 Immunoglobulin domain PF12104 T cell CD4 receptor C terminal region
Function	Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. The antigens presented by class II peptides are derived from extracellular proteins while class I peptides are derived from cytosolic proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class II presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of T-helper cells. In other cells such as macrophages or NK cells, plays a role in differentiation/activation, cytokine expression and cell migration in a TCR/LCK-independent pathway. Participates in the development of T-helper cells in the thymus and triggers the differentiation of monocytes into functional mature macrophages. ; FUNCTION: (Microbial infection) Primary receptor for human immunodeficiency virus-1 (HIV-1) (PubMed:2214026, PubMed:16331979, PubMed:9641677, PubMed:12089508). Down-regulated by HIV-1 Vpu (PubMed:17346169). Acts as a receptor for Human Herpes virus 7/HHV-7 (PubMed:7909607).

> Gene Ontology [ TOP ]
Biological Process	GO:0001819 positive regulation of cytokine production GO:0002250 adaptive immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006948 induction by virus of host cell-cell fusion GO:0007159 leukocyte cell-cell adhesion GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007584 response to nutrient GO:0009615 response to virus GO:0009991 response to extracellular stimulus GO:0010522 regulation of calcium ion transport into cytosol GO:0010524 positive regulation of calcium ion transport into cytosol GO:0010959 regulation of metal ion transport GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019048 modulation by virus of host morphology or physiology GO:0019054 modulation by virus of host process GO:0019058 viral life cycle GO:0019064 fusion of virus membrane with host plasma membrane GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0030260 entry into host cell GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0031667 response to nutrient levels GO:0032355 response to estradiol GO:0032507 maintenance of protein location in cell GO:0032623 interleukin-2 production GO:0032663 regulation of interleukin-2 production GO:0032743 positive regulation of interleukin-2 production GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033273 response to vitamin GO:0033280 response to vitamin D GO:0033674 positive regulation of kinase activity GO:0035397 helper T cell enhancement of adaptive immune response GO:0035821 modification of morphology or physiology of other organism GO:0039663 membrane fusion involved in viral entry into host cell GO:0042035 regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042094 interleukin-2 biosynthetic process GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042107 cytokine metabolic process GO:0042108 positive regulation of cytokine biosynthetic process GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0042742 defense response to bacterium GO:0043270 positive regulation of ion transport GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044003 modification by symbiont of host morphology or physiology GO:0044068 modulation by symbiont of host cellular process GO:0044409 entry into host GO:0044800 multi-organism membrane fusion GO:0044803 multi-organism membrane organization GO:0045058 T cell selection GO:0045076 regulation of interleukin-2 biosynthetic process GO:0045086 positive regulation of interleukin-2 biosynthetic process GO:0045185 maintenance of protein location GO:0045785 positive regulation of cell adhesion GO:0045860 positive regulation of protein kinase activity GO:0046651 lymphocyte proliferation GO:0046718 viral entry into host cell GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050688 regulation of defense response to virus GO:0050690 regulation of defense response to virus by virus GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050792 regulation of viral process GO:0050829 defense response to Gram-negative bacterium GO:0050848 regulation of calcium-mediated signaling GO:0050850 positive regulation of calcium-mediated signaling GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051235 maintenance of location GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051480 regulation of cytosolic calcium ion concentration GO:0051607 defense response to virus GO:0051651 maintenance of location in cell GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0051924 regulation of calcium ion transport GO:0051928 positive regulation of calcium ion transport GO:0055074 calcium ion homeostasis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0061025 membrane fusion GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0070838 divalent metal ion transport GO:0071593 lymphocyte aggregation GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0098542 defense response to other organism GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0001618 virus receptor activity GO:0001948 glycoprotein binding GO:0005201 extracellular matrix structural constituent GO:0015026 coreceptor activity GO:0019865 immunoglobulin binding GO:0042287 MHC protein binding GO:0042289 MHC class II protein binding GO:1990782 protein tyrosine kinase binding
Cellular Component	GO:0005769 early endosome GO:0005788 endoplasmic reticulum lumen GO:0009897 external side of plasma membrane GO:0042101 T cell receptor complex GO:0043235 receptor complex GO:0045121 membrane raft GO:0098552 side of membrane GO:0098589 membrane region GO:0098802 plasma membrane receptor complex GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs) hsa04612 Antigen processing and presentation hsa04640 Hematopoietic cell lineage hsa04660 T cell receptor signaling pathway
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1462054: Alpha-defensins R-HSA-6803157: Antimicrobial peptides R-HSA-173107: Binding and entry of HIV virion R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis R-HSA-8856828: Clathrin-mediated endocytosis R-HSA-388841: Costimulation by the CD28 family R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1461973: Defensins R-HSA-1643685: Disease R-HSA-202424: Downstream TCR signaling R-HSA-162594: Early Phase of HIV Life Cycle R-HSA-202433: Generation of second messenger molecules R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-162909: Host Interactions of HIV factors R-HSA-168256: Immune System R-HSA-5663205: Infectious disease R-HSA-168249: Innate Immune System R-HSA-199991: Membrane Trafficking R-HSA-167590: Nef Mediated CD4 Down-regulation R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters R-HSA-389948: PD-1 signaling R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains R-HSA-449147: Signaling by Interleukins R-HSA-202403: TCR signaling R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis R-HSA-202430: Translocation of ZAP-70 to Immunological synapse R-HSA-5653656: Vesicle-mediated transport R-HSA-180534: Vpu mediated degradation of CD4

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04514 Cell adhesion molecules (CAMs)
hsa04612 Antigen processing and presentation
hsa04640 Hematopoietic cell lineage
hsa04660 T cell receptor signaling pathway

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-1462054: Alpha-defensins
R-HSA-6803157: Antimicrobial peptides
R-HSA-173107: Binding and entry of HIV virion
R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1461973: Defensins
R-HSA-1643685: Disease
R-HSA-202424: Downstream TCR signaling
R-HSA-162594: Early Phase of HIV Life Cycle
R-HSA-202433: Generation of second messenger molecules
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-199991: Membrane Trafficking
R-HSA-167590: Nef Mediated CD4 Down-regulation
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-389948: PD-1 signaling
R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains
R-HSA-449147: Signaling by Interleukins
R-HSA-202403: TCR signaling
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-202430: Translocation of ZAP-70 to Immunological synapse
R-HSA-5653656: Vesicle-mediated transport
R-HSA-180534: Vpu mediated degradation of CD4

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CD4 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19903784	Melanoma	Inhibit immunity ( cell function)	Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Anti-CD4 administration reduced the absolute number of T(reg) cells 9-fold. Effector T-cells generated from anti-CD4-treated mice were significantly (P < 0.0001) more therapeutic in adoptive transfer studies than T cells from multiply vaccinated animals with a full complement of CD4+ cells.
29805109	Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Promote immunity	CD4 gene transduction into iPS-T cells enhanced b3a2 peptide-specific responses via b3a2 peptide-specific TCR. Thus, CD4 modification of CD40Lhigh iPS-T cells generates innate lymphoid helper-like cells inducing bcr-abl-specific TCR signaling that mediates effectiveanti-leukemic CTL responses via DC maturation, showing potential for adjuvant immunotherapy against leukemia.
23363817	Breast Carcinoma	Promote immunity	Furthermore, intratumoral depletion of CD4(+) T cells or blockade of the activating cell-surface protein CD40L inhibits the antitumor response.
23209317	lymphoma	Promote immunity	IL-12/15/18-preactivated NK cells expressed high levels of IL-2Ralpha (CD25), and their rapid in vivo proliferation depended on IL-2 produced by CD4+ T cells. IL-12/15/18-preactivated NK cells accumulated in the tumor tissue and persisted at high cell numbers with potent effector function that required the presence of CD4+ T cells.
17000676	pancreatic carcinoma	Inhibit immunity	CD4+CD25+ regulatory T cells (TR) play a central role in self-tolerance and suppress effective antitumor immune responses. The prevalence of TR was significantly increased in the ductal adenocarcinomas compared with that in the stroma of nonneoplastic inflammation (P<0.0001). T(R) play a role in controlling the immune response against pancreatic ductal carcinoma from the premalignant stage to established cancer. In pancreatic ductal carcinoma, a high prevalence of TR seems to be a marker of poor prognosis.
16899613	Bladder carcinoma	Promote immunity	Immunohistochemical staining for HLA class I, CD4, CD8, CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients who underwent BCG immunotherapy from whom both pretreatment and posttreatment specimens were obtained. Our data show that expression of HLA class I molecules on tumor cells contributes significantly to the therapeutic effect of BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of main effectors in this therapy.
16882704	Melanoma	Promote immunity	We found that genetic removal of CTLA-4 induced activation and acquisition of effector functions in pmel-1 CD8 T cells, resulting in the rapid development of severe autoimmune vitiligo. These effects were abrogated by the removal of the CD4 T-cell population. Therefore, we propose that the lack of CTLA-4 on self/tumor antigen–specific CD8 T cells results in autoimmunity and tumor immunity only in the presence of nonspecific, dysregulated CD4 CTLA-4 / T cells.

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.046	0.892
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.05	0.982
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.124	0.933
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.381	0.275
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.274	0.876
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.515	0.814
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.011	0.982
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.203	0.908
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.294	0.887
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.259	0.491
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.641	0.563
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.12	0.418

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD4
Name	CD4 molecule
Aliases	CD4 antigen (p55); T-cell surface glycoprotein CD4; CD4mut; CD4 receptor; T-cell surface antigen T4/Leu-3; C ......
Chromosomal Location	12p13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD4 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CD4.

ID	Name	Drug Type	Targets	#Targets
DB00098	Antithymocyte immunoglobulin (rabbit)	Biotech	CD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR1	9
DB06241	Clenoliximab	Biotech	CD4	1
DB12698	Ibalizumab	Biotech	CCR5, CD4, CXCR4	3

Browse CD4